Launch of research-use-only adenovirus F41 assay

The assay has been developed by Novacyt to support research efforts following a recent increase in cases of acute hepatitis in children

Paris, France and Camberley, UK – 28 July 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of a research-use-only (RUO) polymerase chain reaction (PCR) assay for the detection of adenovirus F41, in response to recent cases of acute hepatitis in children. This launch expands Novacyt’s genesig® real-time PCR diagnostic product portfolio and is in line with the Company’s strategy to maintain its position as a global first responder in infectious diseases.